Jiangsu Aidea Pharmaceutical Group Co., Ltd. (SHA:688488)
China · Delayed Price · Currency is CNY 15.51
-0.51 (-3.18%)
Mar 30, 2026, 3:00 PM CST
SHA:688488 Revenue
In the year 2025, Jiangsu Aidea Pharmaceutical Group had annual revenue of 720.67M CNY with 72.49% growth. Jiangsu Aidea Pharmaceutical Group had revenue of 168.27M in the quarter ending December 31, 2025, with 41.49% growth.
Revenue
720.67M
Revenue Growth
+72.49%
P/S Ratio
9.35
Revenue / Employee
1.02M
Employees
683
Market Cap
6.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 720.67M | 302.86M | 72.49% |
| Dec 31, 2024 | 417.80M | 6.44M | 1.57% |
| Dec 31, 2023 | 411.36M | 167.14M | 68.44% |
| Dec 31, 2022 | 244.22M | -11.49M | -4.49% |
| Dec 31, 2021 | 255.71M | -33.35M | -11.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.86B |
| Suzhou Fengbei Biotech Stock | 2.81B |
| Xiangxue Pharmaceutical | 1.47B |
| Nanjing Vazyme Biotech | 1.38B |
| Chengdu Kanghua Biological Products | 1.21B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Wuhan Keqian Biology Co.,Ltd | 950.29M |
| Acrobiosystems | 794.52M |